Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer

NCT01693783 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

42

Enrollment

NIH

Sponsor class

Conditions

Cervical Adenocarcinoma
Cervical Squamous Cell Carcinoma
Human Papillomavirus Infection
Recurrent Cervical Carcinoma
Stage IVA Cervical Cancer AJCC v6 and v7
Stage IVB Cervical Cancer AJCC v6 and v7

Interventions

BIOLOGICAL: Ipilimumab
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)